Richard S. Finn, MD - How I Think, How I Treat: Remodeling the HCC Treatment Algorithm With New and Emerging Monotherapy, Combination, and Multimodal Approaches

34:17
 
공유
 

Manage episode 287638000 series 2857008
Player FM과 저희 커뮤니티의 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 콘텐츠는 모두 원 저작자에게 속하며 Player FM이 아닌 작가가 저작권을 갖습니다. 오디오는 해당 서버에서 직접 스트리밍 됩니다. 구독 버튼을 눌러 Player FM에서 업데이트 현황을 확인하세요. 혹은 다른 팟캐스트 앱에서 URL을 불러오세요.
Go online to PeerView.com/AXW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Experts in liver cancer discuss changes to the treatment algorithm for advanced hepatocellular carcinoma (HCC), with an emphasis on selecting and sequencing treatment strategies based on the evidence, guidelines, and patient-related factors. Topics include pivotal safety and efficacy data on multikinase inhibitors, antiangiogenic agents, and immune checkpoint inhibitors used as monotherapy and in combinations with other immunotherapeutic agents or TKIs, clinical trials testing novel strategies and systemic therapies in various settings, and insights from the faculty members on translating treatment advances into clinical practice. Upon completion of this activity, participants should be better able to: Review pivotal safety and efficacy data on available multikinase inhibitors, antiangiogenic agents, single-agent checkpoint inhibitors, and immunotherapy combinations as first- and second-line treatment options for advanced HCC, Assess the validated and potential roles of immune checkpoint inhibitors, including strategies of monotherapy, dual checkpoint inhibition, and combination with targeted therapy, in the advanced HCC disease setting, Summarize ongoing clinical trials testing systemic therapies in the adjuvant setting and in combination with locoregional therapies across the disease spectrum of HCC, Develop safe and effective personalized treatment algorithms for patients with HCC, across multiple lines of therapy, based on current clinical evidence, guideline recommendations, treatment history, underlying liver disease, AFP levels, and individual patient needs.

372 에피소드